title: Adverse effects in neonates exposed to SSRIs and SNRI in late gestation--Motherisk Update 2008.
abstract: Neonates exposed at term to selective serotonine (SSRI) or serotonine-norepinephrine reuptake inhibitors (SNRI) medications may encounter symptoms such as irritability, rigidity, tremor and respiratory distress. Most available data suggest that these self limited symptoms are due to discontinuation of the drug, although there are documented cases of symptoms associated with high serum concentrations in the neonate that subsided when levels fall. Preliminary evidence suggests that the very early respiratory symptoms may not be part of discontinuation but rather part of a reversible form of persistent pulmonary hypertension of the newborn (PPHN).
authors.affiliation: The Motherisk Program, The Hospital for Sick Children, Toronto. gkoren@sickkids.ca
authors.forename: Gideon
authors.initials: G
authors.lastname: Koren
authors.forename: Nina
authors.initials: N
authors.lastname: Boucher
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced*; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011263:Pregnancy Trimester, Third; D018570:Risk Assessment; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D018759:Adrenergic Uptake Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors